Fluicell CEO Newsletter 06, 2021
In the sixth issue of the Fluicell CEO Newsletter for 2021, Victoire Viannay covers Fluicell’s advances in regenerative…
Fluicell makes progress in early development of advanced therapy medicinal products for diabetes based on Biopixlar
Today, Fluicell announces that the company has made important progress in the early development work regarding a medicinal…
16
Sep
2021
Fluicell at Erik Penser Bank Life Science Day
Fluicell’s CEO Victoire Viannay will present the company, what our current focus is and our plans for the…
14
Sep
2021
Pressure differences influence cell division
Cytokinesis, or cell division, is one of the most fundamental process in biology. The division of one cell…
25
Aug
2021
Delårsrapport Q2
Under första hälften av 2021 har Fluicell gjort viktiga framsteg på flera viktiga områden, inte minst genom lanseringen…
20
Aug
2021
Meet Fluicell in July
July comes with several opportunities to meet with Fluicell and discuss everything from single-cell biology and bioprinting to…
28
Jun
2021
Fluicell welcomes Niek Welkenhuysen
Fluicell welcomes Niek Welkenhuysen who started with us in May as a development engineer. Although Niek recently joined…
14
Jun
2021
BioPen Nanoparticle Delivery
We have just released a new application example for BioPen®, covering nanoparticle delivery for single-cell biology. Using Fluicell’s…
10
Jun
2021
Fluicell CEO Newsletter 04, 2021
The announcement of the BioRej™ Advance program for regenerative medicine partnerships in the beginning of May was the…
01
Jun
2021